EGFR and neuroblastoma: Performing a factorial matrix-design combinatorial drug screen on the SH-SY5Y neuroblastoma cells line we found that the FDA approved EGFR/HER2 tyrosine kinase inhibitor lapatinib strongly synergized with YM155.